319 related articles for article (PubMed ID: 36973157)
1. Neuroprotective potential of cannabidiol: Molecular mechanisms and clinical implications.
Tambe SM; Mali S; Amin PD; Oliveira M
J Integr Med; 2023 May; 21(3):236-244. PubMed ID: 36973157
[TBL] [Abstract][Full Text] [Related]
2. Overview of cannabidiol (CBD) and its analogues: Structures, biological activities, and neuroprotective mechanisms in epilepsy and Alzheimer's disease.
Li H; Liu Y; Tian D; Tian L; Ju X; Qi L; Wang Y; Liang C
Eur J Med Chem; 2020 Apr; 192():112163. PubMed ID: 32109623
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.
Rosenberg EC; Patra PH; Whalley BJ
Epilepsy Behav; 2017 May; 70(Pt B):319-327. PubMed ID: 28190698
[TBL] [Abstract][Full Text] [Related]
4. Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders.
Scuderi C; Filippis DD; Iuvone T; Blasio A; Steardo A; Esposito G
Phytother Res; 2009 May; 23(5):597-602. PubMed ID: 18844286
[TBL] [Abstract][Full Text] [Related]
5. Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age.
Crippa JA; Guimarães FS; Campos AC; Zuardi AW
Front Immunol; 2018; 9():2009. PubMed ID: 30298064
[No Abstract] [Full Text] [Related]
6. Neurological Aspects of Medical Use of Cannabidiol.
Mannucci C; Navarra M; Calapai F; Spagnolo EV; Busardò FP; Cas RD; Ippolito FM; Calapai G
CNS Neurol Disord Drug Targets; 2017; 16(5):541-553. PubMed ID: 28412918
[TBL] [Abstract][Full Text] [Related]
7. Cannabidiol, neuroprotection and neuropsychiatric disorders.
Campos AC; Fogaça MV; Sonego AB; Guimarães FS
Pharmacol Res; 2016 Oct; 112():119-127. PubMed ID: 26845349
[TBL] [Abstract][Full Text] [Related]
8. Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia.
Junior NCF; Dos-Santos-Pereira M; Guimarães FS; Del Bel E
Neurotox Res; 2020 Jan; 37(1):12-29. PubMed ID: 31637586
[TBL] [Abstract][Full Text] [Related]
9. Emerging potential of cannabidiol in reversing proteinopathies.
Dash R; Ali MC; Jahan I; Munni YA; Mitra S; Hannan MA; Timalsina B; Oktaviani DF; Choi HJ; Moon IS
Ageing Res Rev; 2021 Jan; 65():101209. PubMed ID: 33181336
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid treatments in epilepsy and seizure disorders.
Devinsky O; Jones NA; Cunningham MO; Jayasekera BAP; Devore S; Whalley BJ
Physiol Rev; 2024 Apr; 104(2):591-649. PubMed ID: 37882730
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson's disease and in comorbidity with psychiatric disorders.
de Fátima Dos Santos Sampaio M; de Paiva YB; Sampaio TB; Pereira MG; Coimbra NC
Basic Clin Pharmacol Toxicol; 2024 May; 134(5):574-601. PubMed ID: 38477419
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals.
Legare CA; Raup-Konsavage WM; Vrana KE
Pharmacology; 2022; 107(3-4):131-149. PubMed ID: 35093949
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotection of Cannabidiol, Its Synthetic Derivatives and Combination Preparations against Microglia-Mediated Neuroinflammation in Neurological Disorders.
Yousaf M; Chang D; Liu Y; Liu T; Zhou X
Molecules; 2022 Aug; 27(15):. PubMed ID: 35956911
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoids as Immune System Modulators: Cannabidiol Potential Therapeutic Approaches and Limitations.
Aziz AI; Nguyen LC; Oumeslakht L; Bensussan A; Ben Mkaddem S
Cannabis Cannabinoid Res; 2023 Apr; 8(2):254-269. PubMed ID: 36413346
[No Abstract] [Full Text] [Related]
15. Cannabis sativa: Much more beyond Δ
Alves P; Amaral C; Teixeira N; Correia-da-Silva G
Pharmacol Res; 2020 Jul; 157():104822. PubMed ID: 32335286
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies.
Reddy DS
Exp Neurol; 2023 Jan; 359():114237. PubMed ID: 36206806
[TBL] [Abstract][Full Text] [Related]
17. Source of cannabinoids: what is available, what is used, and where does it come from?
Specchio N; Pietrafusa N; Cross HJ
Epileptic Disord; 2020 Jan; 22(S1):1-9. PubMed ID: 31941643
[TBL] [Abstract][Full Text] [Related]
18.
Viana MB; de Aquino PEA; Estadella D; Ribeiro DA; Viana GSB
Med Cannabis Cannabinoids; 2022; 5(1):207-219. PubMed ID: 36467781
[TBL] [Abstract][Full Text] [Related]
19. Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease.
Silvestro S; Schepici G; Bramanti P; Mazzon E
Molecules; 2020 Nov; 25(21):. PubMed ID: 33171772
[TBL] [Abstract][Full Text] [Related]
20. Advances and Challenges of Cannabidiol as an Anti-Seizure Strategy: Preclinical Evidence.
Zavala-Tecuapetla C; Luna-Munguia H; López-Meraz ML; Cuellar-Herrera M
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
